Agilis Biotherapeutics Presents on Gene Therapy Pricing Strategies at the 2nd Annual Gene Therapy for Rare Disorders Summit | Business Wire

LYNNFIELD, Mass.–(BUSINESS WIRE)–Agilis Biotherapeutics, Inc. (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced today that Markus Peters, Ph.D., Agilis Chief Commercial Officer (CCO), will give a presentation on the topic “Evaluating Potential Pricing Strategies for Gene Therapies” and participate in the panel discussion “Pricing, Reimbursement & Market Access Considerations” during the 2nd Annual Gene Therapy for Rare Disorders Summit in Boston, MA.

Dr. Peters will discuss opportunities and strategies surrounding pricing and reimbursement in the fast-changing gene therapy space, both for the US and overseas. He will then be joined by other senior industry leaders in a panel discussion on how healthcare systems globally can adapt to the expected entry of an increasing number of innovative treatments with potentially transforming medical benefit.

“All stakeholders — the biopharmaceutical industry, payers, health technology associations, healthcare providers, patient associations, lawmakers and the finance industry — need to continue to collaborate to ensure optimal outcomes for patients with rare disorders and advance a sustainable engine for the development and commercialization of innovative treatments,” said Dr. Peters. “As one of the few companies on the threshold of an anticipated registration and commercial launch of an innovative gene therapy, Agilis has been building capabilities to address issues relating to market access, pricing, payment and reimbursement of advanced therapeutics. Being part of shaping the future is especially important for fast-growing new biotech leaders like Agilis that are spearheading innovation.”

Read complete article here:

Agilis Biotherapeutics Presents on Gene Therapy Pricing Strategies at the 2nd Annual Gene Therapy for Rare Disorders Summit | Business Wire.